Mumps clinical trials
The registry lists 83 studies for Mumps across more than 10 countries. 8 are recruiting or about to start. 17 of them are mainly about Mumps (how this is decided). Per ClinicalTrials.gov, last updated 2026-09-24.
Get an email when these change. Save the Mumps studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
GlaxoSmithKline (24) · Merck Sharp & Dohme LLC (18) · Sanofi Pasteur, a Sanofi Company (6) · Institute of Medical Biology, Chinese Academy of Medical Sciences (3) · Sinovac (Dalian) Vaccine Technology Co., Ltd. (3) · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Institut Pasteur du Cambodge (1)
What is being tested here
Drugs under test in Mumps studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2
- Dec 2026the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines · China National Biotec Group Company Limited
- Sep 2027Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients · Children's Mercy Hospital Kansas City
Who these studies take
Of the 5 Mumps studies recruiting now, 0 (0%) set no upper age limit and 5 (100%) stop at 75 or younger. 4 (80%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (60%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (60%) | 3 (60%) |
| 18 | 3 (60%) | 3 (60%) |
| 30 | 2 (40%) | 2 (40%) |
| 40 | 2 (40%) | 2 (40%) |
| 50 | 1 (20%) | 1 (20%) |
| 65 | 1 (20%) | 1 (20%) |
| 75 | 1 (20%) | 1 (20%) |
| 85 | 0 (0%) | 0 (0%) |
Across all 83 studies, recruiting or not: 92% stop at 75 or younger and 89% at 65; 93% take children; 1% are for women only and 0% for men only; 94% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Mumps studies take
Of 17 phase 3 interventional studies under Mumps, half reached primary completion within 13 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 3 | 13 mo7–24 · 17 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
Studies
Recruiting first, then most recently updated. Showing 50 of 83. Browse all 83 → or search them.
- Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation PatientsRecruitingNCT07195032Phase 41 country
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of AgeNot yet recruitingNCT07742644Phase 36 countries
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of AgeRecruitingNCT07406360Phase 31 country
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT073589101 country
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L VaccinesNot yet recruitingNCT073388511 country
- Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster VaccinationRecruitingNCT05894395Phase 31 country
- Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated VaccinesNot yet recruitingNCT05952505Phase 41 country
- Induction of Immunity Against Measles in Pediatric Liver Transplant RecipientsRecruitingNCT01770119Phase 41 country
- Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMRCompletedNCT02325310Phase 41 country
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 MonthsCompletedNCT06399003Phase 31 country
- A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy AdultsActive, not recruitingNCT06967181Phase 11 country
- Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and InfantsCompletedNCT04398706Phase 24 countries
- Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)CompletedNCT06331702Phase 41 country
- A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of AgeCompletedNCT05630846Phase 25 countries
- The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School StudentsActive, not recruitingNCT06208683Phase 41 country
- Phase II/III of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Healthy Children Aged 5-11Active, not recruitingNCT04591405Phase 2/31 country
- Phase II of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese InfantsActive, not recruitingNCT03133923Phase 21 country
- A Phase I, Safety Study of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese ChildrenCompletedNCT01712906Phase 11 country
- The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella VaccineStatus unknownNCT05279248Phase 41 country
- MMR at 6 Months TrialCompletedNCT03780179Phase 41 country
- Safety Study of Live Attenuated Mumps Vaccines in Junior High School Students Under 14 Years OldCompletedNCT051451661 country
- Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)CompletedNCT00432523Phase 32 countries
- Measles, Mumps, and Rubella (MMR) Immunity in College StudentsCompletedNCT009628191 country
- Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy InfantsCompletedNCT05065177Phase 31 country
- Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps VaccineCompletedNCT04364399Phase 41 country
- Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of AgeCompletedNCT02184572Phase 35 countries
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of LifeCompletedNCT01681992Phase 37 countries
- Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) VaccineCompletedNCT02880865Phase 41 country
- Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of AgeCompletedNCT00861744Phase 22 countries
- Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of AgeCompletedNCT01702428Phase 36 countries
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of AgeCompletedNCT01621802Phase 33 countries
- Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working SeedsCompletedNCT00892775Phase 22 countries
- Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)CompletedNCT00092430Phase 3
- Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)CompletedNCT00326183Phase 4
- Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)CompletedNCT01536405Phase 3
- Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of AgeCompletedNCT00578175Phase 21 country
- Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy ChildrenCompletedNCT01506193Phase 31 country
- ProQuad® Intramuscular vs SubcutaneousCompletedNCT00402831Phase 3
- Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTMCompletedNCT00969436Phase 31 country
- Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136CompletedNCT00751348Phase 31 country
- Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and OlderCompletedNCT02058563Phase 33 countries
- Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)CompletedNCT00432042Phase 32 countries
- Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)CompletedNCT00566527Phase 3
- Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy InfantsCompletedNCT02692599Phase 31 country
- Safety Study of ProQuad® rHA in Infants (V221-037)CompletedNCT00560755Phase 3
- Observational Study to Assess Protection to Mumps in Children Received One-dose Mumps-containing VaccineCompletedNCT029019901 country
- Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) VaccineCompletedNCT03160820Phase 41 country
- A Study of ProQuad™ in Healthy Children in Korea (V221-023)TerminatedNCT00839917Phase 3
- V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)CompletedNCT00109343Phase 3
- Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)CompletedNCT00092404Phase 2